Searched for
GSK PHARMA EARNINGS
Ahead of Market: 10 things that will decide stock market action on FridayIndian equities witnessed sharp swings before ending lower amid expiry-day volatility and rising geopolitical concerns. Profit booking in b...- GSK Pharma sheds 2% as Q3 profit drops, expenses riseTotal income in October-December 2021 stood at Rs 826.24 crore as compared with Rs 805.89 crore in the year-ago period, PTI reported.
- GSK to boost spending power of pharma business post break-upGlaxoSmithKline will lay out plans to boost the spending power of its research-focused pharmaceuticals business at an investor day. GSK's s...
- Trending stocks: Shares of GSK Pharma gain 4%The stock quoted a 52-week high of Rs 1744.0 and a 52-week low of Rs 1087.75.
- GSK Pharma tumbles 12% after posting Rs 660-crore Q3 lossThe company's consolidated revenue from operations stood at Rs 778.59 crore for the quarter under consideration.
- GSK Pharma profit up 6.53% at Rs 102.85 cr in Jan-Mar quarterGlaxoSmithKline Pharmaceuticals today reported 6.53 per cent increase in standalone net profit at Rs 102.85 crore for the Jan-March quarter.
- Bulls on the rampage, tailwinds take FMCG, pharma to fresh highsSharp drop in crude prices, slowing rate of inflation and downward trend in the interest rate cycle have created strong tailwinds for consu...
- Pick-up in local market boosts pharma MNCsA pick-up in the local pharma market augurs well for MNCs which are still recovering from the adverse impact of drug price control on high-...
- GSK Pharma open offer begins today; stock hits 52-week highGSK Pharma continued to attract investor attention after its UK-based parent company GlaxoSmithKline’s voluntary open offer started today.
- Domestic pharma companies may gain as MNCs set to swallow bitter marketing pillA cautious strategy adopted by MNCs in promoting medicines could affect MNCs, including GSK, and impact their growth prospects in the India...
- GSK Pharma: Price control may prove costly for companyMultinational drug maker GSK Pharma’s good show in 2012 masks a key concern for the company, the new drug pricing control order.
- Q3 Earnings Preview: US market to help pharma put up healthy numbersThe weakening of the rupee during a good part of the quarter to December will also help boost export realisations.
- GSK Pharma: Investors must be careful of the competitive threats it faces in IndiaWhile the company's performance in the June quarter was strong sequentially, it will be interesting to see GSK's strategies to overcome the...
- GSK Pharma: New launches, stronger field force could helpNet sales for the quarter have been lower than that logged in the preceding quarters of September and March 2011 and stand almost at the sa...
- GSK Pharma: Domestic market slump to hurt growth prospectsThe company posted a 13% growth in net sales and 8% growth in operating profit - its best performance in the past three quarters.
- Hold onto GSK Pharma: CK Narayan"GSK is a hold and you look to any big dips to buy."
- Glaxosmithkline Pharma: Vaccine business to help maintain margin leadGlaxoSmithKline Pharma has grown across all its business segments and is on track to maintain its target of growing at close to 12-13 % ann...
- Pharma cos to disclose gifts to doctorsGSK to publish info on website, other MNC subsidiaries may follow suit.
- More drug MNCs join the stake-hike bandwagonAfter the two leading pharma multinationals recently increased their stakes in their Indian units, people connected with the industry say t...
- Cipla overtakes GSK to become top Indian pharma companyCipla has established its lead in the domestic pharma retail market to become the no. 1 company for the first seven months this year.
Load More
